Filing Flows › Companies › Inovio Pharmaceuticals › Report card
Inovio Pharmaceuticals earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate3 of 4 reports beat the EPS estimate
Inovio Pharmaceuticals (INO) beat the analysts' EPS estimate in 3 of its last 4 reports (75%), by -14.5% on average. Next report: Nov 10, 2026, analysts expect EPS −$0.20.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS |
|---|---|---|---|---|---|
| Q to Jun 2026 | Aug 12, 2026 | −$0.24 | −$0.24 | +0.6% | −$0.07 |
| Q to Mar 2026 | May 13, 2026 | −$0.33 | −$0.31 | +4.7% | −$0.28 |
| Q to Dec 2025 | Mar 12, 2026 | −$0.34 | −$0.28 | +19.6% | — |
| Q to Sep 2025 | Nov 10, 2025 | −$0.48 | −$0.87 | -82.8% | −$0.87 |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Inovio Pharmaceuticals: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.